According to reports from Brickwork Ratings, the company has assigned a 'BWR BBB/Stable' rating to the bank loan facilities of Anlon Healthcare Limited. The rating reflects the company's strong fundamentals in the pharmaceutical sector, with the stable outlook indicating a low likelihood of rating change over the medium term. As reported by Anlon Healthcare, the rating outlook may be revised to 'positive' in case the revenue and profitability margins show sustained improvement, while it may be revised to 'negative' if the financial risk profile goes down. The latest announcement includes a 'BBB/Stable' rating for Fund Based Long Term facilities amounting to ₹23.60 crore, alongside the removal of a previous 'BB+ Stable' rating and withdrawal of a 'C' rating from the ISSUER NOT COOPERATING category*. The rating was officially assigned on September 15, 2026 at 11:00 a.m. (IST) and is available on the company's website.
As reported by Anlon Healthcare, the company's operating income reached ₹176.54 crore for FY26, with a net worth of ₹209.77 crore. The company has projected revenues of ₹270 crore for FY2027, demonstrating strong growth trajectory. Additionally, Anlon Healthcare maintains a moderate cash and bank balance of ₹3.41 crore and net cash accruals of ₹30.92 crore, indicating healthy liquidity position. The company's consolidated net profit jumped 87.61% to ₹6.66 crore on a 162.94% increase in revenue to ₹87.56 crore in Q1 FY7 compared with Q1 FY6. The company successfully completed its ₹121.03 crore IPO in late August 2025, drawing high investor demand with an overall subscription rate over 7x (led by retail at 47x). By listing on the BSE and NSE on September 3, 2025, the company effectively secured the growth capital needed to clear debt, expand manufacturing, and scale its API operations.
As reported by Brickwork Ratings, the rating is supported by the management's extensive experience in the pharmaceutical industry, significant growth in scale of operations, improved profitability margins, a robust capital structure with low leverage, and healthy debt-coverage metrics. The company is led by Mr. Punitkumar Rameshbhai Rasadia (Managing Director, aged 40 years), who is a Post Graduate with 16 years of experience, and Mr. Meet Atulkumar Vachhani (Whole time Director, aged 46 years) with 20+ years of experience. The board includes independent directors with significant experience, including Mr. Krishna Murty Kannepalli (aged 70 years) with 25 years of experience and Mr. Anandbhai Natwarlal Katkoria (aged 70 years) with 36 years of experience. The company demonstrates strong liquidity with a current ratio of 2.57 times in FY 2026, ISCR of 10.67 times, and DSCR of 1.03 times, indicating adequate capacity to meet both interest and principal repayment obligations.
According to Brickwork Ratings, the rating is constrained by intense market competition and strict regulatory compliance risks, including quality norms and government price controls. The company operates under stringent regulatory frameworks across domestic and international markets, with any non-compliance with standards such as GMP or adverse observations from regulatory authorities potentially resulting in warning or suspension of manufacturing facilities. Technological obsolescence risk remains a concern as rapid advancements in pharmaceutical processes may render existing products or manufacturing processes less competitive. The rating outlook may be revised to 'positive' if the company achieves projected revenues above ₹270 crore for FY2027, while improving net profitability margins over 18% and strengthening liquidity profile. Conversely, the ratings could be downgraded if there is a decline in revenue & profit margins below 10%, increase in overall gearing, and weakening of debt protection metrics.
As reported by Brickwork Ratings, Anlon Healthcare Limited is a research-driven manufacturer of active pharmaceutical ingredients (APIs), bulk drugs, and advanced pharmaceutical intermediates. The company operates from its registered office in Rajkot and its manufacturing facility at Pipaliya, Gondal Road, Rajkot, serving domestic and international customers with quality-focused manufacturing solutions. The company is among the few Indian manufacturers of products such as Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol, which are widely used in pain management and anti-inflammatory therapies. The company demonstrates adequate ESG profile with environmental stewardship through green chemistry and efficient manufacturing processes, maintaining a zero-fatality record in FY 2025-26 while enforcing strict workplace safety systems. The company maintains formal policies on prevention of sexual harassment to protect its 119 employees and actively contributes to local communities through CSR investments in education, health, and community development.
